Zelira Therapeutics Limited Stock Performance
| ZLDAF Stock | USD 0.23 0.00 0.00% |
The firm maintains a market beta of 0.12, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Zelira Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Zelira Therapeutics is expected to be smaller as well. At this point, Zelira Therapeutics has a negative expected return of -0.12%. Please make sure to check out Zelira Therapeutics' jensen alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Zelira Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Zelira Therapeutics Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
| Begin Period Cash Flow | 5 M | |
| Total Cashflows From Investing Activities | -207.8 K |
Zelira |
Zelira Therapeutics Relative Risk vs. Return Landscape
If you would invest 26.00 in Zelira Therapeutics Limited on September 26, 2025 and sell it today you would lose (3.00) from holding Zelira Therapeutics Limited or give up 11.54% of portfolio value over 90 days. Zelira Therapeutics Limited is currently producing negative expected returns and takes up 3.8022% volatility of returns over 90 trading days. Put another way, 34% of traded otc stocks are less volatile than Zelira, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Zelira Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zelira Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Zelira Therapeutics Limited, and traders can use it to determine the average amount a Zelira Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0312
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ZLDAF |
Based on monthly moving average Zelira Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zelira Therapeutics by adding Zelira Therapeutics to a well-diversified portfolio.
Zelira Therapeutics Fundamentals Growth
Zelira OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Zelira Therapeutics, and Zelira Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zelira OTC Stock performance.
| Return On Equity | -0.34 | |||
| Return On Asset | -0.21 | |||
| Operating Margin | (8.57) % | |||
| Current Valuation | 4.97 M | |||
| Shares Outstanding | 9.58 M | |||
| Price To Earning | 20.00 X | |||
| Price To Book | 0.29 X | |||
| Price To Sales | 4.37 X | |||
| Revenue | 1.54 M | |||
| EBITDA | (11.77 M) | |||
| Cash And Equivalents | 2.75 M | |||
| Cash Per Share | 0.29 X | |||
| Total Debt | 500.91 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 3.68 X | |||
| Cash Flow From Operations | (9.43 M) | |||
| Earnings Per Share | (1.05) X | |||
| Total Asset | 37.7 M | |||
About Zelira Therapeutics Performance
By analyzing Zelira Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Zelira Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Zelira Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Zelira Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia. Zelda Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Zelira Therapeutics performance evaluation
Checking the ongoing alerts about Zelira Therapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Zelira Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Zelira Therapeutics generated a negative expected return over the last 90 days | |
| Zelira Therapeutics has some characteristics of a very speculative penny stock | |
| Zelira Therapeutics has high historical volatility and very poor performance | |
| The company reported the revenue of 1.54 M. Net Loss for the year was (11.95 M) with profit before overhead, payroll, taxes, and interest of 601.57 K. | |
| Zelira Therapeutics Limited has accumulated about 2.75 M in cash with (9.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 44.0% of the company outstanding shares are owned by insiders |
- Analyzing Zelira Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Zelira Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Zelira Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Zelira Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Zelira Therapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Zelira Therapeutics' otc stock. These opinions can provide insight into Zelira Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Zelira OTC Stock analysis
When running Zelira Therapeutics' price analysis, check to measure Zelira Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zelira Therapeutics is operating at the current time. Most of Zelira Therapeutics' value examination focuses on studying past and present price action to predict the probability of Zelira Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zelira Therapeutics' price. Additionally, you may evaluate how the addition of Zelira Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Stocks Directory Find actively traded stocks across global markets |